B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01846923|
Recruitment Status : Unknown
Verified May 2013 by Vana Spoulou, Aghia Sophia Children's Hospital of Athens.
Recruitment status was: Active, not recruiting
First Posted : May 6, 2013
Last Update Posted : May 6, 2013
Aghia Sophia Children's Hospital of Athens
Information provided by (Responsible Party):
Vana Spoulou, Aghia Sophia Children's Hospital of Athens
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Actual Primary Completion Date :||February 2012|
|Study Completion Date :||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Papadatou I, Lagousi T, Kattamis A, Spoulou V. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with beta-thalassemia: assessing the need for booster. Ann Hematol. 2019 Mar;98(3):775-779. doi: 10.1007/s00277-019-03615-z. Epub 2019 Jan 25.
Papadatou I, Piperi C, Alexandraki K, Kattamis A, Theodoridou M, Spoulou V. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with beta-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2014 Sep 15;59(6):862-5. doi: 10.1093/cid/ciu409. Epub 2014 May 30.